BioXcel Therapeutics (BTAI) Accounts Payables (2017 - 2026)

BioXcel Therapeutics' Accounts Payables history runs 10 years deep, the most recent figure standing at $16.2 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 5.16% year-over-year to $16.2 million in Q1 2026; TTM through Mar 2026 was $16.2 million, a 5.16% increase from a year earlier, with the FY2025 full-year figure at $14.7 million, down 8.06% from the prior year.
• Accounts Payables improved to $16.2 million in Q1 2026 per BTAI's latest filing, from $14.7 million in the prior quarter.
• Across five years, Accounts Payables topped out at $17.2 million in Q1 2024 and bottomed at $5.1 million in Q1 2022.
• The 5-year median for Accounts Payables is $13.7 million (2023), against an average of $12.4 million.
• Across the five-year window, Accounts Payables jumped 141.13% in 2022 and fell 10.28% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $10.2 million in 2022, then jumped by 33.5% to $13.7 million in 2023, then rose by 17.11% to $16.0 million in 2024, then dropped by 8.06% to $14.7 million in 2025, then advanced by 10.52% to $16.2 million in 2026.
• Per Business Quant, the three latest BTAI Accounts Payables figures stand at $16.2 million (Q1 2026), $14.7 million (Q4 2025), and $16.3 million (Q3 2025).